Juliana Bue‐Valleskey
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Diabetes Management and Research, Diabetes Treatment and Management, Pancreatic function and diabetes, Diabetes and associated disorders, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → The role of neuropeptide Y in the antiobesity action of the obese gene product(1995)1,511 cited
- → Non‐alcoholic fatty liver disease ( NAFLD ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes(2017)182 cited
- → Mathematical models of diabetes progression(2008)111 cited
- → Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study(2020)89 cited
- → Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5(2015)81 cited
- → Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study(2020)63 cited
- → Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial(2023)54 cited
- → Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes(2023)54 cited
- → Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial(2016)44 cited
- → Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy(2020)36 cited